Business
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
FEATURED STORIES
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Martin Shkreli will not be able to delay paying nearly $25 million he owes from a civil lawsuit that he and his company employed on Daraprim.
Athenex announced that it is scaling its operations by more than 50%, while Zosano Pharma announced that it is reducing its workforce by around 31%.
California-based Apexigen and two other companies are planning to move to the Nasdaq Stock Exchange following their mergers with SPACs.
Now, Kosacz is helping to guide the company’s experimental oncology treatments toward regulatory approval.
Sir Mene Pangalos said the company was considering not submitting it to the FDA if it finds it is “banging its head against a brick wall indefinitely.”
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
AstraZeneca and Merck announced their Lynparza drug reduced the risk of death by 32% compared to placebo for specific breast cancer patients.
In his new book, Warp Speed, Paul Mango said the realization that many healthcare workers didn’t want the vaccine, for instance, was shocking.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Biogen returned the rights to a dry age-related macular degeneration (dAMD) drug to Catalyst Biosciences. Biogen also ended the partnership regarding other dry AMD.